(Q38175864)

30 August 2017

Immunology and immunotherapy of chronic myeloid leukemia (English)

1 reference

30 August 2017

chronic myeloid leukemia

0 references

1 reference

Satu Mustjoki

3

0 references

author name string

Mette Ilander

series ordinal

1

1 reference

30 August 2017

Can Hekim

series ordinal

2

1 reference

30 August 2017

language of work or name

1 reference

1 March 2014

1 reference

Current hematologic malignancy reports

30 August 2017

1 reference

30 August 2017

9

1 reference

30 August 2017

1

1 reference

30 August 2017

17-23

1 reference

https://scigraph.springernature.com/pub.10.1007/s11899-013-0190-1

30 August 2017

0 references

cites work

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Evidence for BCR-ABL-dependent dysfunctions of iNKT cells from chronic myeloid leukemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Characterization of chronic myeloid leukemia stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Antigens in chronic myeloid leukemia: implications for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Expression and distribution of PPP2R5C gene in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Aurora-A kinase: a novel target of cellular immunotherapy for leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Selective killing of candidate AML stem cells by antibody targeting of IL1RAP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Graft-versus-leukemia effect of HLA-haploidentical central-memory T-cells expanded with leukemic APCs and modified with a suicide gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Natural killer cell mediated missing-self recognition can protect mice from primary chronic myeloid leukemia in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Profound inhibition of antigen-specific T-cell effector functions by dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Immunological effects of interferon-alpha on chronic myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Induction of sustained deep molecular response in a patient with chronic-phase T315I-mutated chronic myeloid leukemia with interferon-α monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11899-013-0190-1

Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.

21 January 2018

1 reference

12 December 2020

Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha

1 reference

12 December 2020

Dasatinib combined with interferon-alfa induces a complete cytogenetic response and major molecular response in a patient with chronic myelogenous leukemia harboring the T315I BCR-ABL1 mutation

1 reference

12 December 2020

Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses.

1 reference

12 December 2020

Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units

1 reference

12 December 2020

Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells

1 reference

12 December 2020

Identification of a novel peptide derived from the M-phase phosphoprotein 11 (MPP11) leukemic antigen recognized by human CD8+ cytotoxic T lymphocytes.

1 reference

12 December 2020

Graft-versus-leukemia reactions after bone marrow transplantation

1 reference

12 December 2020

The biological basis for immunotherapy in patients with chronic myelogenous leukemia

1 reference

12 December 2020

Increased natural killer cells and decreased CD3(+)CD8(+)CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib

1 reference

12 December 2020

Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation.

1 reference

12 December 2020

Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients

1 reference

12 December 2020

Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa

1 reference

12 December 2020

Quantitative and functional analyses of CD4(+) CD25(+) FoxP3(+) regulatory T cells in chronic phase chronic myeloid leukaemia patients at diagnosis and on imatinib mesylate

1 reference

12 December 2020

10.1007/S11899-013-0190-1

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

0 references

1 reference